CLINICAL TRIALS PROFILE FOR ROMAZICON
✉ Email this page to a colleague
All Clinical Trials for ROMAZICON
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00781482 ↗ | Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem | Withdrawn | Abiant, Inc. | Phase 4 | 1969-12-31 | This study will compare the interactions of a placebo and two FDA-approved sleeping medications, Eszopiclone (Lunesta) and Zolpidem (Ambien), with certain chemical receptors in the brain. We want to show that we can use positron emission tomography images to measure the binding of these medications to the receptors. |
| NCT00781482 ↗ | Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem | Withdrawn | Sunovion | Phase 4 | 1969-12-31 | This study will compare the interactions of a placebo and two FDA-approved sleeping medications, Eszopiclone (Lunesta) and Zolpidem (Ambien), with certain chemical receptors in the brain. We want to show that we can use positron emission tomography images to measure the binding of these medications to the receptors. |
| NCT00781482 ↗ | Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem | Withdrawn | Kettering Health Network | Phase 4 | 1969-12-31 | This study will compare the interactions of a placebo and two FDA-approved sleeping medications, Eszopiclone (Lunesta) and Zolpidem (Ambien), with certain chemical receptors in the brain. We want to show that we can use positron emission tomography images to measure the binding of these medications to the receptors. |
| NCT02048969 ↗ | Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS | Withdrawn | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1/Phase 2 | 2014-06-01 | The purpose of this study is to test feasibility of measuring flumazenil-induced changes in cortical GABA levels observed with localized 1H-MRS in relation to changes in severity of hepatic encephalopathy (HE) in subjects with non-alcoholic liver cirrhosis. This study is a double-blind, placebo-controlled, randomized, cross-over design. |
| NCT02048969 ↗ | Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS | Withdrawn | Yale University | Phase 1/Phase 2 | 2014-06-01 | The purpose of this study is to test feasibility of measuring flumazenil-induced changes in cortical GABA levels observed with localized 1H-MRS in relation to changes in severity of hepatic encephalopathy (HE) in subjects with non-alcoholic liver cirrhosis. This study is a double-blind, placebo-controlled, randomized, cross-over design. |
| NCT02899156 ↗ | Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure | Terminated | University of California, Davis | Phase 4 | 2016-03-01 | Delirium within the intensive care unit (ICU) is associated with poor outcomes such as increased mortality, ICU and hospital length of stay (LOS), and time on mechanical ventilation. Benzodiazepine (BZD) exposure is an independent risk factor for development of delirium. Reversal of hypoactive delirium represents a potential opportunity for reducing duration of delirium and subsequent complications. This is a single-center randomized, double-blind, placebo-controlled study of critically ill adult patients with benzodiazepine-associated hypoactive delirium. The hypothesis is that flumazenil continuous infusion may reverse hypoactive delirium associated with BZD exposure and thereby reduce duration of delirium and ICU LOS. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ROMAZICON
Condition Name
Clinical Trial Locations for ROMAZICON
Trials by Country
Clinical Trial Progress for ROMAZICON
Clinical Trial Phase
Clinical Trial Sponsors for ROMAZICON
Sponsor Name
